Angelica S I Loskog

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi request reprint Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines
    Angelica Loskog
    Clinical Immunology Division, Rudbeck Laboratory C11 Uppsala University, Uppsala, Sweden
    J Urol 177:353-8. 2007
  2. ncbi request reprint Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors
    Angelica Loskog
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Dag Hammarskjoldsvag, 20 751 85, Uppsala, Sweden
    Cancer Immunol Immunother 55:588-97. 2006
  3. ncbi request reprint Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy
    A Loskog
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Sweden
    Lab Anim 39:384-93. 2005
  4. ncbi request reprint AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model
    Angelica S I Loskog
    Rudbeck Laboratory, Clinical Immunology Division, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 11:8816-21. 2005
  5. ncbi request reprint Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells
    A Loskog
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
    Leukemia 20:1819-28. 2006
  6. ncbi request reprint CD40L - a multipotent molecule for tumor therapy
    Angelica Loskog
    Clinical Immunology Division, Uppsala University, 751 85 Uppsala, Sweden
    Endocr Metab Immune Disord Drug Targets 7:23-8. 2007
  7. doi request reprint AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial
    Per Uno Malmstrom
    Division of Urology, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 16:3279-87. 2010
  8. doi request reprint Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma
    Sara Westberg
    University Animal Hospital, Swedish University of Agricultural Sciences SLU, Uppsala, Sweden
    J Immunother 36:350-8. 2013
  9. pmc T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis
    Joachim Burman
    Department of Neurosciences, Uppsala University, Uppsala, Sweden Department of Neurology, Uppsala University Hospital, Uppsala, Sweden Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
    Immunology 140:211-9. 2013
  10. doi request reprint AdCD40L--crossing the valley of death?
    Gustav Ullenhag
    Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, Sweden
    Int Rev Immunol 31:289-98. 2012

Collaborators

Detail Information

Publications17

  1. ncbi request reprint Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines
    Angelica Loskog
    Clinical Immunology Division, Rudbeck Laboratory C11 Uppsala University, Uppsala, Sweden
    J Urol 177:353-8. 2007
    ..We are developing immunostimulating gene therapy for treating bladder cancer. In this study we constructed an immunological profile of patients with bladder carcinoma to understand which obstacles must be circumvented...
  2. ncbi request reprint Dendritic cells engineered to express CD40L continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors
    Angelica Loskog
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Dag Hammarskjoldsvag, 20 751 85, Uppsala, Sweden
    Cancer Immunol Immunother 55:588-97. 2006
    ..Thus, CD40L-engineered DCs are robust Th1-promoting ones that are resistant to Tr1/Th3-signaling via IL10 and TGFbeta...
  3. ncbi request reprint Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy
    A Loskog
    Clinical Immunology Division, Rudbeck Laboratory, Uppsala University, Sweden
    Lab Anim 39:384-93. 2005
    ..Given the possibility for efficient genetic modification of the bladder and the presence of known tumour antigens, the MB49 models can be used in innovative ways to explore immunogene therapy...
  4. ncbi request reprint AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model
    Angelica S I Loskog
    Rudbeck Laboratory, Clinical Immunology Division, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 11:8816-21. 2005
    ..CD40L stimulation of dendritic cells induces interleukin-12 expression that drives Th1 type of immune responses with activation of cytotoxic T cells...
  5. ncbi request reprint Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells
    A Loskog
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
    Leukemia 20:1819-28. 2006
    ..These effects are seen whether the chimeric T cells are derived from normal donors or from patients with B-cell chronic lymphocytic leukemia, indicating the potential for clinical application in B cell malignancies...
  6. ncbi request reprint CD40L - a multipotent molecule for tumor therapy
    Angelica Loskog
    Clinical Immunology Division, Uppsala University, 751 85 Uppsala, Sweden
    Endocr Metab Immune Disord Drug Targets 7:23-8. 2007
    ..In this survey, different types and mechanisms of CD40L-based therapy will be discussed from bench to bedside...
  7. doi request reprint AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial
    Per Uno Malmstrom
    Division of Urology, Uppsala University, Uppsala, Sweden
    Clin Cancer Res 16:3279-87. 2010
    ..Immunostimulating gene therapy with adenoviral vectors expressing CD40 ligand (AdCD40L) has shown efficacy in tumor models. CD40 ligand stimulates systemic immunity and may be effective in local and invasive human disease...
  8. doi request reprint Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma
    Sara Westberg
    University Animal Hospital, Swedish University of Agricultural Sciences SLU, Uppsala, Sweden
    J Immunother 36:350-8. 2013
    ..Our results suggest that local AdCD40L therapy is safe and could have beneficial effects in dogs, supporting further treatment development. Clinical translation to human patients is in progress. ..
  9. pmc T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis
    Joachim Burman
    Department of Neurosciences, Uppsala University, Uppsala, Sweden Department of Neurology, Uppsala University Hospital, Uppsala, Sweden Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
    Immunology 140:211-9. 2013
    ..In conclusion, we demonstrate circumstantial evidence for the removal of autoreactive T-cell clones as well as development of tolerance after HSCT. These results parallel the long-term disease remission seen after HSCT. ..
  10. doi request reprint AdCD40L--crossing the valley of death?
    Gustav Ullenhag
    Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, Sweden
    Int Rev Immunol 31:289-98. 2012
    ..This review discusses the currently unfolding mechanisms of action of AdCD40L gene therapy and its possibilities to reach clinical care...
  11. pmc Both CD4+ FoxP3+ and CD4+ FoxP3- T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro
    Camilla A Lindqvist
    Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Sweden
    Immunology 133:296-306. 2011
    ..In conclusion, cytotoxic populations of CD4(+) T cells, including Tregs, are present in patients with B-cell malignancy and may be an important factor in immune-related disease control...
  12. pmc Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia
    Lisa Christiansson
    Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
    PLoS ONE 8:e55818. 2013
    ..These escape mechanisms should be monitored in trials to understand their importance and how to overcome the immune suppression...
  13. pmc CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
    Moa Fransson
    Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    J Neuroinflammation 9:112. 2012
    ..Here, we propose gene engineering to achieve CNS-targeting Tregs from naïve CD4 cells and demonstrate their efficacy in the EAE model...
  14. pmc T regulatory cells in B-cell malignancy - tumour support or kiss of death?
    Camilla A Lindqvist
    Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden
    Immunology 135:255-60. 2012
    ..In this review, we discuss the origin and function of Treg cells and their role in patients with B-cell tumours...
  15. pmc T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies
    Camilla A Lindqvist
    Division of Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Immunology 131:371-6. 2010
    ..Recombinant sCD25 could suppress T-cell proliferation in vitro. In conclusion, the release of sCD25 by Treg cells may be a mechanism to deprive IL-2 and thereby inhibit anti-tumour T-cell responses...
  16. pmc The T-cell pool is anergized in patients with multiple sclerosis in remission
    Moa E Fransson
    Clinical Immunology Division, Uppsala University, Uppsala, Sweden
    Immunology 126:92-101. 2009
    ..In conclusion, patients in relapse/remission demonstrate in vitro T-cell responses that are both Th1 and Th17 that, while in remission, appear to be controlled by tolerogenic mechanisms yet to be investigated...
  17. doi request reprint The Janus faces of CD40 in cancer
    Angelica S I Loskog
    Rudbeck Laboratory, Clinical Immunology Division, Uppsala University, Uppsala, Sweden
    Semin Immunol 21:301-7. 2009
    ..Here, we provide an overview of the multifaceted functions of the CD40 pathway in cancer and its emerging role in the treatment of malignancy...